Iambic Therapeutics (NASDAQ:IAM) Shares Climb 11.8% – Here’s Why

Iambic Therapeutics, Inc. (NASDAQ:IAM)’s stock price shot up 11.8% during trading on Monday. The company traded as high as $11.37 and last traded at $11.37. 165,709 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 738,781 shares. The stock had previously closed at $10.17.

Analysts Set New Price Targets

Several analysts have issued reports on IAM shares. Wall Street Zen raised Iambic Therapeutics to a “hold” rating in a research report on Saturday. Jefferies Financial Group started coverage on Iambic Therapeutics in a report on Tuesday. They issued a “buy” rating and a $35.00 price target on the stock. JPMorgan Chase & Co. began coverage on Iambic Therapeutics in a research report on Monday. They issued an “overweight” rating and a $22.00 price target for the company. Citigroup initiated coverage on Iambic Therapeutics in a research note on Monday. They set a “buy” rating and a $22.00 price objective for the company. Finally, Bank of America initiated coverage on Iambic Therapeutics in a research note on Monday. They set a “buy” rating and a $30.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $27.25.

Iambic Therapeutics Price Performance

Insider Buying and Selling

In other news, Director Evan Lockwood Rachlin bought 718,750 shares of the firm’s stock in a transaction that occurred on Friday, October 16th. The stock was bought at an average price of $16.00 per share, with a total value of $11,500,000.00. Following the completion of the transaction, the director directly owned 2,588,248 shares of the company’s stock, valued at approximately $41,411,968. The trade was a 38.45% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

About Iambic Therapeutics

Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.